News
Petition urges Government to introduce menstrual leave
A petition calling on the UK government to introduce menstrual leave for women with gynaecological conditions has gathered nearly 75,000 signatures.
The campaign needs 100,000 signatures by 29 January 2026 for a debate in Parliament.
It would allow three extra sick days a year for people with endometriosis, adenomyosis and polycystic ovary syndrome (PCOS). Similar legislation already exists in Spain and Portugal.
Women across Merseyside have spoken about the impact these conditions have on their working lives.
Becca Jade Burrows, 29, from St Helens, has experienced symptoms including heavy bleeding, pain, bloating and nausea for four years while awaiting diagnosis of endometriosis and adenomyosis.
“This is something that should be discussed because when flare ups happen, its impossible to work with the pain you’re in,” she said.
“I’ve recently started a new job and worry about needing to take time off as I’m new, so this would help.”
Liverpool student Molly Nicholls, 20, was diagnosed with stage two endometriosis in 2024 following a diagnostic laparoscopy (a keyhole procedure to look inside the abdomen), having first sought help at age 12.
“It’s just so hard and the pain during flare ups is just excruciating,” she said.
“Most women have more than one gynaecological condition. A lot of people don’t understand how these conditions impact daily life.”
Ceri Bruinsma, 44, a self-employed massage therapist from Liverpool, was diagnosed with umbilical endometriosis, a rare form affecting 0.5 to one per cent of women, after she began bleeding from her belly button.
“I’ve had pain before that feels like when I was in labour,” she said. “Three days isn’t much to ask for.”
The government says it has no plans to introduce menstrual leave, pointing instead to the Employment Rights Bill introduced in 2024 and existing protections under the Equality Act 2010.
Marie Rimmer, MP for St Helens South and Whiston, said: “I have spoken to many women who have lived with the pain of endometriosis for years before being taken seriously.
“No one should be made to feel that their pain is something they just have to put up with.”
Cancer
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Wellness3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur6 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health







